[Evaluation for medical management on catamenial pneumothorax].

article OA: closed CC0 ⤵ 2 in-corpus citations
View on OpenAlex View on PubMed
AI-generated summary by gemini-2.5-flash-lite, 2026-06-08

This study evaluated hormonal therapy combined with OK-432 chemical pleurodesis as a treatment for catamenial pneumothorax, finding it an appropriate strategy with long-term recurrence-free outcomes.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Catamenial pneumothorax (CP) is one of the clinical manifestations of endometriosis, therefore the systemic hormonal therapy is indispensable and should be the 1st choice for CP treatment. However, it is refractory and repeats a recurrence, so that a combined or sequential adjuvant treatment becomes necessary. From 2003 to 2009, 5 patients with CP were treated at our institution. All patients had right-sided pneumothorax and the history of pelvic endometriosis. By thoracoscopic examination, diaphragmatic abnormalities, such as defect, pinhole, or brown spot, were identified in all patients. We performed hormonal therapy combined with chemical pleurodesis using OK-432, as an initial treatment. Two patients have been free of recurrence for 24 and 53 months, respectively. Three patients who refused or interrupted hormonal therapy caused a recurrence, but were successfully managed with the addition of pleurodesis and continuing hormonal therapy. At present, all patients are asymptomatic with 13 to 92 months recurrence-free period. From the long-term results, our therapeutic strategy consisted of hormonal therapy and chemical pleurodesis is considered appropriate.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Gonadotropin-Releasing Hormone Picibanil Pleurodesis Pneumothorax Adult Female Gonadotropin-Releasing Hormone Humans Picibanil Pleurodesis Pneumothorax

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (2)

Cited by (2)

Source provenance

europepmc
last seen: 2026-08-24T06:08:07.662257+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:16:11.197438+00:00
License: CC0 · commercial use OK